TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00097838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
Study: NCT04453163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Patient will undergo a surgery in percutaneous vertebroplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertebroplasty
Description: Patient will undergo a surgery in percutaneous vertebroplasty
Study: NCT02854371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadoxetic acid enhanced liver MRI
Description: Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG R15
Description: ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
Study: NCT03061604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray
Description: Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Blood transfusion will be administered to all patients if needed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion will be administered to all patients if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone will be administered to all patients on daily basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone will be administered to all patients on daily basis
Study: NCT02756598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil I
Description: bolus dose of sufentanil 1 microgram/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil II
Description: bolus dose of sufentanil 0.5 microgram/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol I
Description: Continued dose of propofol 0.03 mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol II
Description: Continued dose of propofol 0.06 mg/kg/min
Study: NCT01471275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 250 mg or 500mg three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiangtangtiaozhi decoction
Description: 15 grams each time, twice a day, with boiled water
Study: NCT03761004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa
Description: single dose of WD-1603, BID dose of WD-1603 and Sinemet IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: single dose of WD-1603, BID dose of WD-1603 and Sinemet IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa
Description: single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
Study: NCT03066778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion on Day 1 of each cycle prior to chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline solution
Description: IV infusion on Day 1 of each cycle prior to chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion on Day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion on Days 1, 2 and 3 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: IV infusion on Days 1, 2 and 3 of each cycle
Study: NCT02508415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: OHE, scaling root planing, mouth wash
Study: NCT02734225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Recovery
Description: Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Recovery
Description: Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance and proprioception training using parallel bars, unstable plates, ramps and stairs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance and proprioception training using parallel bars, unstable plates, ramps and stairs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometric Platform Training
Description: Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
Study: NCT05262790

Intervention type: OTHER
Intervention: This is not an intervention study

Intervention type: OTHER
Intervention: This is not an intervention study

Intervention type: OTHER
Intervention: This is not an intervention study
Study: NCT04186897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Description: Occlusal contacts on the functional and non-functional cusps were reduced.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham occlusal reduction
Description: The occlusal surface left intact. No actual occlusal reduction.
Study: NCT03782805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol (Euro-Pharm International, Canada)
Description: The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
Study: NCT03089801

Intervention type: OTHER
Intervention: Tablet-Enabled Video Telehealth
Description: Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
Study: NCT01464853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with fatty acids
Description: Enteral Feeding to provide 25 kcal/Kg/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Enteral Feeding to provide 25 kcal/Kg/day
Study: NCT01756508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
Study: NCT02570750

Intervention type: BEHAVIORAL
Intervention: QUESTIONNAIRE ON SMOKING HABITS
Description: Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points.

Intervention type: BEHAVIORAL
Intervention: QUESTIONNAIRE ON SMOKING HABITS
Description: Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points.
Study: NCT04553003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids+hepatoprotectant
Description: Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepatoprotectant
Description: Participants received hepatoprotectants (i.v.gtt.) for 7 days.
Study: NCT02372435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shortening of the interval of two-stage prosthesis exchange
Description: The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shortening of the interval of two-stage prosthesis exchange
Description: The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
Study: NCT01865604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Study: NCT02463006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porous variant of Bioactive Glass.
Description: Flap surgery with Porous variant of Bioactive Glass.
Study: NCT00607178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo for influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
Study: NCT02463006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non porous variant of Bioactive Glass.
Description: Flap surgery with non-Porous variant of Bioactive Glass.
Study: NCT04792047

Intervention type: DIAGNOSTIC_TEST
Intervention: HRP frequency, plaque compostion and local immune-inflammatory activation
Description: HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: HRP frequency, plaque compostion and local immune-inflammatory activation
Description: HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
Study: NCT04718311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral lichen clinical Healing evaluation
Description: Treatments were topically applied for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lichen clinical Healing evaluation
Description: Treatments were topically applied for 5 days
Study: NCT02509793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine
Description: Xenazine, pill, dose to effect, three times a day, for 12 weeks
Study: NCT03326232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
Study: NCT01618461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug indication icons
Description: Icons illustrate the purpose of each medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug indication icons
Description: Icons illustrate the purpose of each medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured instructions
Description: Graphical format shows what time(s) of day each medication should be taken

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured instructions
Description: Graphical format shows what time(s) of day each medication should be taken
Study: NCT01304303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1023 I
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1023 II
Description: IV administration
Study: NCT04719429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cricket-derived Protein
Description: Beverage containing 25 g cricket-derived protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beef-derived Protein
Description: Beverage containing 25 g beef-derived protein
Study: NCT04400071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Music Engagement
Description: Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio Storybooks
Description: Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
Study: NCT02192853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 4: placebo tablet
Study: NCT00791492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
Study: NCT02232555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02588664

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS Intervention
Description: * A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services.
Study: NCT03034135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram/Copper
Description: Disulfiram/copper gluconate is taken three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ is given per standard of care
Study: NCT00910546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visicoil gold marker 0.7 x 20 mm
Description: CT - guided implantation into lung tumors
Study: NCT02529098

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: fMRI
Description: functional magnetic resonance imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional magnetic resonance imaging
Study: NCT00600158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine with hydromorphone
Description: bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: lidocaine 2 mg/min intravenously (or 3 mg/kg in patients \> 70 kg)
Study: NCT02966821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
Study: NCT01239082

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: One time screening Colonoscopy to screen for colorectal cancer

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FIT
Description: Annual FIT testing
Study: NCT04402450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided suprainguinal fascia iliaca nerve block
Description: After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pericapsular nerves group of the hip block
Description: After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
Study: NCT02274779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIGARD
Description: Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical.
Study: NCT01430117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Poa pratensis allergen extract, positive control and negative control
Description: Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Study: NCT03991988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events.
Study: NCT01140828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole 20mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole Placebo
Description: one tab once daily
Study: NCT00462176

Intervention type: PROCEDURE
Intervention: multidisciplinary laparoscopy
Description: Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.

Intervention type: OTHER
Intervention: Questionnaires
Description: All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).